Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
hMPV mRNA LNP 1
- Development stage
- Unknown
- Lead developer
- Sanofi
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
hMPV mRNA LNP 1 is an investigational messenger RNA (mRNA) vaccine candidate encapsulated in a lipid nanoparticle (LNP) formulation. It is designed to prevent lower respiratory tract disease caused by human metapneumovirus (hMPV), and in some formulations also targets respiratory syncytial virus (RSV). The vaccine encodes the fusion protein of hMPV and/or RSV, delivered via lipid nanoparticles to promote cellular uptake and antigen expression. The encoded antigens are derived from specific viral strains and are not engineered with prefusion stabilizing mutations; however, they predominantly express in the prefusion conformation. This approach aims to elicit neutralizing antibody responses against both viruses. Clinical studies have shown that the vaccine increases neutralization titers against hMPV and is being evaluated for safety and immunogenicity in both children and older adults[1][2][3][4].
- Other names
- Respiratory syncytial virus mRNA vaccine - Sanofi
02
Targets
RSV F (Respiratory syncytial virus fusion protein)HMPV F (Human metapneumovirus fusion protein)
Beyond the preview
Go deeper on hMPV mRNA LNP 1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on hMPV mRNA LNP 1.